Vitiligo as durvalumab's immune-related adverse event in lung cancer

被引：1

作者：

Rogado, Jacobo ^{[1
,4
]}

Buendia-Castano, Diego ^{[2
,4
]}

Alonso-Garcia, Soledad R. ^{[3
,4
]}

机构：

[1] Hosp Univ Infanta Leonor, Med Oncol Dept, Gran via este,80, Madrid 28031, Spain

[2] Hosp Univ Infanta Leonor, Dermatol Dept, Gran via este,80, Madrid 28031, Spain

[3] Hosp Univ Infanta Leonor, Pathol Dept, Gran via este,80, Madrid 28031, Spain

[4] Univ Complutense Madrid, Madrid, Spain

来源：

MEDICINA CLINICA | 2022年 / 158卷 / 07期

关键词：

NIVOLUMAB;

D O I：

10.1016/j.medcli.2021.07.024

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：341 / 342

页数：3

共 5 条

[1] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[3] Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes [J].

Freeman-Keller, Morganna ;

Kim, Youngchul ;

Cronin, Heather ;

Richards, Allison ;

Gibney, Geoffrey ;

Weber, Jeffrey S. .

CLINICAL CANCER RESEARCH, 2016, 22 (04) :886-894

[4] Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients [J].

Rogado, J. ;

Sanchez-Torres, J. M. ;

Romero-Laorden, N. ;

Ballesteros, A., I ;

Pacheco-Barcia, V ;

Ramos-Levi, A. ;

Arranz, R. ;

Lorenzo, A. ;

Gullon, P. ;

Donnay, O. ;

Adrados, M. ;

Costas, P. ;

Aspa, J. ;

Alfranca, A. ;

Mondejar, R. ;

Colomer, R. .

EUROPEAN JOURNAL OF CANCER, 2019, 109 :21-27

[5] Dermatologic Reactions to Immune Checkpoint Inhibitors Skin Toxicities and Immunotherapy [J].

Sibaud, Vincent .

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (03) :345-361

← 1 →